求助文献2篇

jianlindunev

1Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy: Analysis of the EMPHASIS-HF Study / K7 l( \' o8 }3 f/ Z7 _
http://circheartfailure.ahajournals.org/content/6/4/711.long
# V( x' L" E7 z5 Q. r2，Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy: Results From the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) http://circheartfailure.ahajournals.org/content/7/1/51.long
6 C/ A2 ?6 L3 P* \3，Incidence, Predictors and Outcomes Related to Hypo and Hyperkalemia in Severe Heart Failure Patients Treated with a Mineralocorticoid Receptor Antagonist.
; c$ p8 w' e& w6 `1 t0 [* Chttp://www-ncbi-nlm-nih-gov.ezpr ... Receptor+Antagonist
7 d, r" s) \- Y3 T+ Z0 o2 p* {